• Founded on over two decades of research, the Company was formed in 2014 and listed on the UK stock market.
  • From the outset, we constructed a library of bacteria isolated from healthy human samples, which now stands at more than 4,000 strains.
  • We have built a drug discovery platform, known as MicroRx, which has shown the ability to rapidly identify bacteria from our library that have therapeutically relevant effects.
  • Starting in late 2014, the Company has initiated 15 live biotherapeutic programmes across a broad range of diseases.
  • The Company has received FDA Orphan Designation for its programmes in paediatric Crohn’s disease and paediatric Ulcerative Colitis.
  • We have developed humanised preclinical models, which since 2015 have allowed us to test our products in more disease-relevant settings and improve their translational potential.
  • The Company commenced a clinical study of Blautix in patients with IBS in 2015. This trial has now been completed and successfully reached its primary objective.
  • In November 2015, 4D announced that it had developed a live biotherapeutic which shows efficacy in preclinical models of cancer.
  • The Company has established its own development and manufacturing facility, completed in 2016, which is dedicated to the production of our live biotherapeutics.
  • In August 2016, we commenced dosing in patients of our live biotherapeutic for paediatric Crohn’s disease.

BACK TO TOP